Dr. Brian J. Feinstein, D.O.

Medicare patients and services

Medicare patients, 2024

2,090

Services billed

25,162

Patients’ average age

77

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 32 payments worth $5,335 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 20 industry-funded studies in 2025, from 8 companies. The companies reported $1,714,615 in research payments for these studies, mostly to the institutions running them.

• A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
  Pfizer Inc.
• Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
  Sanofi US Services Inc. · Active, not recruiting · NCT05492578
• A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
  Sanofi US Services Inc. · Active, not recruiting · NCT06407934
• Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
  Sanofi US Services Inc. · Terminated · NCT06058156
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  Sanofi US Services Inc. · Active, not recruiting · NCT06241118
• A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
  Incyte Corporation
• A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
  Sanofi US Services Inc. · Completed · NCT06015308
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
  Sanofi US Services Inc. · Completed · NCT06130566
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
  E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06136741
• Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
  Sanofi Pasteur Inc. · Recruiting · NCT06316297

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Delray Beach

• Janet D. Allenby, D.O.
• Jessica Bernstein, DO
• Howard A. Bueller, M.D.
• Eliahou Cohen, MD
• Andrea Colton, MD
• Lori A. Fiessinger, M.D.
• Heidi Gold, M.D.
• Steven M. Hacker, MD